AbbVie (NYSE:ABBV) has been actively advancing its oncology portfolio with recent presentations at the AACR Annual Meeting, ...

Data to be presented on ABBV-514, a novel CCR8 targeting antibody, in Phase 1 for non-small cell lung cancer, head and neck cancer and other solid tumors. Other presentations highlight key ...

AbbVie (NYSE:ABBV) recently showcased significant advances in oncology, particularly with the introduction of new pipeline ...

particularly with the introduction of new pipeline products like ABBV-969 and ABBV-514 at the AACR Annual Meeting 2025, reflecting a commitment to innovative cancer treatments. Despite a downturn ...